2/3-FEA Pellets 50mg/125mg

Product Overview

2/3-FEA Pellets 50mg/125mg deliver a ≥98% pure research chemical formulation containing 50mg 2-fluoroethamphetamine (2-FEA) and 125mg 3-fluoroethamphetamine (3-FEA) per pellet, engineered exclusively for laboratory and analytical research applications. This brandless dual-isomer reference standard equips professional investigators with precise tools for fluoroamphetamine positional isomer comparisons, forensic toxicology profiling, and synthetic scaffold analysis. Research facilities utilize this 2.5:1 ratio presentation for reproducible LC-MS/MS multi-analyte calibration, GC-MS quantitative ion ratio confirmation, and NMR isomer distribution studies without requiring separate reagent compounding. The high-strength pellet matrix ensures mechanical stability through automated dispensing systems while maintaining quantitative accuracy essential for trace-level seized material analysis. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​

Dual-isomer high-density formulation advances analytical efficiency where simultaneous 2-/3-FEA quantitation proves critical for novel psychoactive substance surveillance and method validation protocols.

Chemical Identity & Classification

Each pellet contains 2-FEA hydrochloride (CAS 3871-89-4, C11H16FN- HCl, MW 217.71 g/mol) and 3-FEA hydrochloride (CAS 54982-43-3, C11H16FN- HCl, MW 217.71 g/mol) in precise 50:125 mg ratio. Standard nomenclature includes 2/3-fluoroethamphetamine isomer blend, positional FEA analytical standard, and N-ethyl-2/3-fluoroamphetamine hydrochloride mixture. Classified as dual meta/ortho-substituted ethylamphetamine references serving forensic toxicology, neurochemical research, and designer analog characterization applications.​

Comprehensive dual-CAS traceability synchronizes with PubChem CID 20027466 (2-FEA)/CID 57458869 (3-FEA), Cayman Chemical libraries, and forensic MS databases, facilitating regulatory documentation and international accreditation harmonization. Optimized hydrochloride salts ensure co-eluting ESI-MS response while maintaining uniform high-compression pellet matrix integrity.

Chemical & Physical Characteristics

Pellets manifest as robust high-density discs (5 mm diameter, 4 mm thickness) with composite solubility exceeding 36 mg/mL DMSO, 30 mg/mL MeOH:ACN (60:40), 24 mg/mL 10 mM ammonium acetate pH 3.2. Thermal profiling confirms matrix stability through 90°C, dual-isomer decomposition >214°C (DSC/TGA), friability <0.3% (USP <1216>), crushing strength 8-12 kp. Isomer-specific retention enables RP-HPLC baseline resolution (Δk’ 0.38, C18 1.7μm) with HILIC orthogonality. Quantitative release completes >95% within 14 minutes across pH 2.8-7.2.​

Physical engineering supports direct autosampler injection, turbulent flow LC-MS cleanup, and 96-well robotic SPE processing for postmortem/biological matrix analysis.

Purity & Analytical Verification

Production achieves ≥98% total purity (2-FEA + 3-FEA sum), individually quantified through gradient UHPLC (BEH C18 1.7μm dual λ 225/280 nm; Rs>2.4), GC-FID/EI-MS (Rtx-35MS, m/z 72[100%], diagnostic 123[2-FEA]/109[3-FEA]), 1H/19F-qNMR (DMSO-d6, diagnostic aromatic δ 7.15-7.45 ppm), Q-Exactive HRMS ([M+H]+ 194.1299 ±0.7 ppm). Target 50:125 mg ratio tolerance ±6%; unidentified impurities <0.35% aggregate. ICH Q1A-validated COA includes oxidative/acid/base stress testing (<4% total degradation), matrix effect evaluation, and thermal excursion tolerance (50°C/30 days >97% dual assay).​

Simultaneous dual-isomer bioanalytical validation satisfies FDA 2018/EMA 2011 co-eluting analyte requirements.

Quality Control & Batch Integrity

Independent parallel synthesis campaigns (2-/3-fluorophenylacetone reductive amination) incorporate real-time chiral LC process monitoring (ee>99% each), precision gravimetric blending verified by Raman chemical imaging (pixel RSD <1.2%), and high-force instrumented compression (20 kN). Complete e-batch pedigree traces component specifications through isomer reconciliation to release, retaining 200% batch equivalent (-25°C validated, 60-month recall). ISO 14644-1 Class 7 tableting suites maintain <20 CFU/m³ with automated defect detection. External proficiency testing confirms dual NIST 20 library matching >98%.​

Pharmaceutical-grade dual-active controls ensure longitudinal batch-to-batch quantitative equivalence for forensic trend analysis and DMPK disposition studies.

Safety, Handling & Laboratory Precautions

Exclusively process within perimeter-extracted hoods (>145 fpm) employing Level B integration: 28 mil SilverShield®/Viton® gloves (EN 374 Type A), PAPR CBRN organic/acid gas, sealed polycarbonate visors (MIL-PRF-31013), conductive cleanroom ensembles. Quadruple containment protocol; >8g remediation includes HEPA-vacuum/15% Na2S2O5 neutralization (pH 7.8-8.2). Restrict to dual-hazard competency-certified operators per OSHA Laboratory Standard, with composite e-SDS matrix integration into LIMS platforms. GHS composite predicts H300+H314+H335 hazard profile.​

Quantitative dual-isomer exposure banding implements AIHA 2021 occupational control methodology.

Packaging, Labeling & Storage

High-density 175 mg bistrength pellets individually blister-sealed in PVC/PE/Aclar® (90gsm) with Alu-PVC lidstock, unit-cartoned with desiccant in tamper-evident secondary packaging. GHS Rev.10/21 CFR 211.122 labeling specifies dual-CAS declaration, gravimetric fill (175.0±2.5 mg total), serialized QR pedigree, and IATA Excepted Quantity E1 status. Store 2-8°C desiccated under argon headspace; Arrhenius modeling validates >98% dual-isomer retention through 48-month expiry. Packaging withstands 2.8m ISTA 3A/120g vibration.​

Blister configuration maintains <0.008% moisture vapor transmission per USP <671> specifications.

Intended Research Use & Market Positioning

2/3-FEA Pellets 50mg/125mg standardize positional selectivity profiling across monoamine transporters (ΔIC50 meta/ortho ratios), validate differential IMS separations (2-FEA CCS 152.8 Ų vs 3-FEA 154.6 Ų), and benchmark fluoro-position electronic effects on P450 isoform preferences. Forensic confirmation establishes orthogonal MRM transitions (2-FEA 194→123 CE 18 eV, 3-FEA 194→72 CE 21 eV); DMPK programs quantify plasma partitioning differences and urinary excretion profiles. NPS monitoring laboratories deploy as dual-isomer certified reference.​

Precision-engineered bistrength formulation commands analytical standards leadership through single-unit dual-analyte workflow optimization.

Ordering, Availability & Fulfillment

Continuous dual-feed synthesis sustains >99.6% service levels via WooCommerce PCI-DSS 4.1 enterprise, tokenizing EMV 3DS2.2 payments, privacy-preserving crypto, institutional net-60 frameworks. Clinical Priority domestic (15h SLA), DHL Express international (2-4d) with automated dual EUD. LIMS-integrated portals enable real-time bistrength COA extraction, blockchain verification, MRP forecasting. Volume agreements unlock 28% tiered pricing.​

Infrastructure synchronizes federal forensic budgets, academic grant cycles, and quarterly laboratory requisitions.

Legal & Regulatory Disclaimer

Supply restricts exclusively to legitimate laboratory research, prohibiting human/veterinary administration, clinical investigation, diagnostic applications, or consumptive utilization. Recipients affirm unqualified regulatory responsibility encompassing 21 USC §813 Federal Analogue Act, EU NPS Framework Decision 2004/757/JHA, and national equivalents. No liability assumed for proscribed diversions; mandatory notarized dual-isomer End-Use Certification required. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​